Effects of Cyp2c19 and P2y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel After Acute Ischemic Cerebrovascular Disease

1. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al.; American Heart Association; American Stroke Association. Update to the AHA/ ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008; 39(5): 1647-1652.10.1161/STROKEAHA.107.189063419833518322260Search in Google Scholar

2. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011; 76(6 Suppl): S85-S90.10.1016/j.wneu.2011.07.02322182277Search in Google Scholar

3. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, et al. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Int J Cardiol. 2013; 168(2): 1594-1596.10.1016/j.ijcard.2013.01.04023402725Search in Google Scholar

4. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7): 1648-165210.1161/01.ATV.0000225288.74170.dc16675725Search in Google Scholar

5. Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, et al. Feasibility of a microarraybased point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int. 2013; 2013: 154073. doi: 10.1155/2013/154073.10.1155/2013/154073362560523607088Search in Google Scholar

6. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Gene: CYP2C19. Available from: http://www.pharmgkb.org/gene/PA124. Accessed November 10 2014.Search in Google Scholar

7. Scott SA, Sangkuhl K, Gardner EE, Stein CM. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Parmacol Therapeut. 2011; 90(2): 328-332.10.1038/clpt.2011.132323430121716271Search in Google Scholar

8. Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb. 2014; 21(1): 64-76.10.5551/jat.1895224088578Search in Google Scholar

9. Kim KA, Song WG, Lee HM, Joo HJ, Park JY. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Thromb Res. 2013; 132(2): 221-226.10.1016/j.thromres.2013.06.02023849096Search in Google Scholar

10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84(5): 891-896.10.1055/s-0037-1614133Search in Google Scholar

11. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994; 269(2): 772-777.Search in Google Scholar

12. Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999; 19(4): 1142-1147.10.1161/01.ATV.19.4.1142Search in Google Scholar

13. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thromb Res. 2011; 128(1): 47-5310.1016/j.thromres.2011.02.019Search in Google Scholar

14. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005; 36(7): 1394-1399.10.1161/01.STR.0000169922.79281.a5Search in Google Scholar

15. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013; 106(10): 517-527.10.1016/j.acvd.2013.06.055Search in Google Scholar

16. Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, et al. Effects of coexisting polymorphisms of CYP2 C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl). 2013; 126(6): 1069-1075.Search in Google Scholar

17. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996; 348 (9038): 1329-1339.10.1016/S0140-6736(96)09457-3Search in Google Scholar

18. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003; 91(9): 1123-1125.10.1016/S0002-9149(03)00163-2Search in Google Scholar

19. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23): 2908-2913.10.1161/01.CIR.0000072771.11429.8312796140Search in Google Scholar

20. Spokoyny I, Barazangi N, Jaramillo V, Rose J, Chen C, Wong C, et al. Reduced clopidogrel metabolism in a multiethnic population: Prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis. 2014; 23(4): 694-698.10.1016/j.jstrokecerebrovasdis.2013.06.00823849748Search in Google Scholar

21. Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: Are we there yet? Stroke. 2010; 41(12): 2997-3002.10.1161/STROKEAHA.110.594069301468321030701Search in Google Scholar

22. US Food and Drug Administration. Clopidogrel black box warning. Available from: http:// www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm. Accessed November 10, 2014.Search in Google Scholar

23. Terpening C. Clopidogrel: A pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol. 2010; 4(1): 117-128. 10.4137/CMC.S4323299893521151850Search in Google Scholar